• FirefoxInstall the new Firefox »
  •  Dow Down0.06% Nasdaq Up0.42%

    More On MOR.DE



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Morphosys AG (MOR.DE)

    74.76 Down 2.32(3.01%) Feb 26
    Add to Portfolio
    ProfileGet Profile for:
    Morphosys AG
    Lena-Christ-Strasse 48
    Martinsried, 82152
    Germany - Map
    Phone: 49 8989 9270
    Fax: 49 89 8992 7222
    Website: http://www.morphosys.com

    Index Membership:N/A
    Full Time Employees:328

    Business Summary 

    MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Morphosys AG

    Key Executives 
    Dr. Simon E. Moroney Ph.D.,
    Chairman of Management Board and Chief Exec. Officer
    Mr. Jens Holstein ,
    Chief Financial Officer and Member of Management Board
    Dr. Marlies Sproll , 57
    Chief Scientific Officer and Member of Management Board
    Dr. Arndt Schottelius , 49
    Chief Devel. Officer and Member of Management Board
    Mr. Klaus De Wall ,
    Head of Accounting & Controlling
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.